Background: The effectiveness of pre-implantation genetic testing for aneuploidy (PGT-A) remains a topic of intense debate.
Objectives: Is to determine the optimal time for PGT-A biopsies.
Methods: Up until May 2024, MEDLINE/PubMed, Embase, and the Cochrane Central Library were searched thoroughly for relevant literature. PGT-A with comprehensive chromosomal screening (CCS) on Days 3 and 5 was used in 11 randomized controlled studies.
Results: In the overall population, PGT-A did not increase live-birth rates (LBR) per patient (RR:1.11; 95%CI:0.87-1.42; n=1513; I2=75%). Nonetheless, PGT-A reduced the whole population's miscarriage rate (RR:0.45; 95%CI:0.25-0.80; n=912; I2=49%). Remarkably, PGT-A increased cumulative LBR per patient (RR:1.36; 95%CI:1.13-1.64; n=580; I2=12%). Only the day-5 biopsy procedure showed enhanced LBR per ET in terms of optimal scheduling (RR: 1.37; 95% CI: 1.03-1.82; I2=72%).
Conclusion: PGT-A only increased live-birth rates when applied to embryos at the blastocyst phase; it had no effect on clinical results for the overall population